Pharma Medical News about Antibiotics, Antifungal

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Issues in the design and interpretation of antifungal drug trials in the critically ill
Current Opinion in Infectious Diseases, 10/28/09

Ostrosky–Zeichner L – Although there are limited data supporting preventive and early therapeutic strategies, their use is recommended in highly selected patients and settings. Although critically ill patients are under–represented in clinical trials of antifungals conducted for the purpose of licensing, most experts agree that it is reasonable to extrapolate from these data until specific trials are conducted.

<< Previous
Microbicides Development Programme: design of a phase III trial...

Next >>
Epocrates Boosts Blackberry Support

New imagining technique could lead to better antibiotics and cancer drugs
EurekAlert, 11/10/09 Relevance Score: 65%

Infections in acute myeloid leukemia: an analysis of 382 febrile episodes
Medical Oncology, 10/28/09 Relevance Score: 65%

Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole
British Journal of Clinical Pharmacology, 11/10/09 Relevance Score: 64%

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
Journal of Clinical Oncology, 10/09/09 Relevance Score: 64%

Inadequate Antibiotic Therapy in Solid Organ Transplant Recipients is Associated with a Higher Mortality Rate
Surgical Infections, 10/01/09 Relevance Score: 46%